Treatment of circadian rhythm disorders
US-9060995-B2 · Jun 23, 2015 · US
Treatment of circadian rhythm disorders
US9549913B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9549913-B2 |
| Application number | US-201314374257-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 25, 2013 |
| Priority date | Jan 26, 2012 |
| Publication date | Jan 24, 2017 |
| Grant date | Jan 24, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of entraining a patient's cortisol circadian rhythm to a 24-hour circadian rhythm and maintaining said 24-hour circadian rhythm, the method comprising: treating the patient by orally administering to the patient tasimelteon once daily before a target bedtime. 2. The method of claim 1 , wherein the patient is light perception impaired (LPI). 3. The method of claim 1 , wherein the patient is totally blind. 4. The method of claim 1 , wherein the patient suffers from Non-24-Hour Sleep-Wake Disorder. 5. The method of claim 1 , wherein the 24-hour circadian rhythm comprises a 24-hour sleep-wake cycle in which the patient awakens at or near a target wake time following a daily sleep period of approximately 7 to 9 hours. 6. The method of claim 1 , wherein the tasimelteon is orally administered 0.5 hours to 1.5 hours before the target bedtime. 7. The method of claim 1 , wherein treatment is initiated on a day in which the patient's urinary cortisol acrophase is predicted to be within about 5.5 hours before a target wake time and about 2.5 hours after the target wake time. 8. The method of claim 1 , wherein treatment is initiated on a day in which the patient's urinary aMT6s acrophase is predicted to be within about 5.5 hours before a target wake time and about 2.5 hours after the target wake time. 9. The method of claim 1 , wherein the administering includes administering between about 10 mg and 100 mg of tasimelteon. 10. The method of claim 1 , wherein the administering includes administering between about 20 mg and about 50 mg of tasimelteon. 11. The method of claim 1 , wherein the administering includes administering about 20 mg of tasimelteon. 12. The method of claim 4 , wherein the 24-hour circadian rhythm comprises a 24-hour sleep-wake cycle in which the patient awakens at or near a target wake time following a daily sleep period of approximately 7 to 9 hours. 13. The method of claim 5 , wherein the tasimelteon is orally administered 0.5 hours to 1.5 hours before the target bedtime. 14. The method of claim 6 , wherein the administering includes administering about 20 mg of tasimelteon.
Assignees
Inventors
Classifications
of the suprarenal hormones · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Drugs for disorders of the endocrine system · CPC title
Hypnotics; Sedatives · CPC title
Psychostimulants, e.g. nicotine, cocaine · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9549913B2 cover?
- Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
- Who is the assignee on this patent?
- Vanda Pharmaceuticals Inc
- What technology area does this patent fall under?
- Primary CPC classification G16H50/20. Mapped technology areas include Physics.
- When was this patent published?
- Publication date Tue Jan 24 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).